Expertise in
25
conditions

Dr. Santosh Kesari

Providence Saint Johns Medical Foundation
Los Angeles, CA
Expertise in
25
conditions
Specialties:Neurology
Offers Telehealth
Expertise in
25
conditions
OverviewInsuranceLocationsClinical Research

Overview

Santosh Kesari is a Neurologist in Los Angeles, California. Dr. Kesari is highly rated in 25 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Gliomatosis Cerebri, and Tissue Biopsy.

His clinical research consists of co-authoring 313 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Saint John's Health Center
Providence Little Company Of Mary Med Ctr Torrance
Providence Mission Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

PROVIDENCE SAINT JOHNS MEDICAL FOUNDATION
11645 Wilshire Blvd, Suite 600, Los Angeles, CA 90025
310-477-5558

Additional Areas of Focus

Dr. Kesari has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2024
Intervention Type: Biological
Study Drug: TAEK-VAC-HerBy
Study Phase: Phase 1
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drugs: OKN-007, Temozolomide (TMZ)
Study Phase: Phase 2
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
Enrollment Status: Completed
Publish Date: May 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Enrollment Status: Completed
Publish Date: November 08, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Nivolumab, Ipilimumab, Bevacizumab, Metronomic Temozolomide, 5-day Temozolomide, Lomustine
Study Phase: Phase 1
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Neflamapimod
Study Phase: Phase 2
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab, and Phase 1 Dose-Escalation Study of Enterally-administered Marizomib With Bevacizumab
Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab, and Phase 1 Dose-Escalation Study of Enterally-administered Marizomib With Bevacizumab
Enrollment Status: Completed
Publish Date: June 08, 2022
Intervention Type: Drug
Study Drugs: Marizomib, Bevacizumab
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer
A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer
Enrollment Status: Completed
Publish Date: March 10, 2022
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 1
Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Unknown
Publish Date: December 16, 2021
Intervention Type: Biological
Study Drug: AV-GBM-1
Study Phase: Phase 2
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: October 19, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase 1b, Multicenter, Open-Label Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma
Phase 1b, Multicenter, Open-Label Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug, Device, Radiation
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 17 Less Clinical Trials

310 Total Publications

Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.
Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.
Journal: Oncotarget
Published: November 22, 2024
Similar Doctors
Expertise in
22
conditions
Dr. Timothy Cloughesy
Neurology | Hematology Oncology
Expertise in
22
conditions
Dr. Timothy Cloughesy
Neurology | Hematology Oncology

The Regents Of The University Of California

150 Medical Plz, 
Los Angeles, CA 
 (1.3 mi)
310-825-9989
Languages Spoken:
English
Offers Telehealth

Timothy Cloughesy is a Neurologist and a Hematologist Oncology provider in Los Angeles, California. Dr. Cloughesy is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
50
conditions
Dr. Susan L. Perlman
Neurology
Expertise in
50
conditions
Dr. Susan L. Perlman
Neurology

The Regents Of The University Of California

150 Medical Plz, 
Los Angeles, CA 
 (1.3 mi)
310-825-9989
Languages Spoken:
English
Offers Telehealth

Susan Perlman is a Neurologist in Los Angeles, California. Dr. Perlman is highly rated in 50 conditions, according to our data. Her top areas of expertise are Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

Expertise in
38
conditions
Dr. Perry B. Shieh
Neurology | Neuromusculoskeletal Medicine
Expertise in
38
conditions
Dr. Perry B. Shieh
Neurology | Neuromusculoskeletal Medicine

The Regents Of The University Of California

150 Medical Plz, 
Los Angeles, CA 
 (1.3 mi)
310-825-9989
Languages Spoken:
English
Offers Telehealth

Dr. Perry Shieh, MD is a Neurology Specialist in Los Angeles, CA and has over 22 years of experience in the medical field. He graduated from Johns Hopkins University School Of Medicine in 2000. He is affiliated with medical facilities Ronald Reagan UCLA Medical Center and Casa Colina Hospital. Dr. Shieh is highly rated in 38 conditions, according to our data. His top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Spinal Muscular Atrophy Type 2.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile